Meredith A Skiba, Sarah M Sterling, Shaun Rawson, Shuhao Zhang, Huixin Xu, Haoran Jiang, Genevieve R Nemeth, Morgan S A Gilman, Joseph D Hurley, Pengxiang Shen, Dean P Staus, Jihee Kim, Conor McMahon, Maria K Lehtinen, Howard A Rockman, Patrick Barth, Laura M Wingler, Andrew C Kruse
G-protein-coupled receptors (GPCRs) are key regulators of human physiology and are the targets of many small-molecule research compounds and therapeutic drugs. While most of these ligands bind to their target GPCR with high affinity, selectivity is often limited at the receptor, tissue and cellular levels. Antibodies have the potential to address these limitations but their properties as GPCR ligands remain poorly characterized. Here, using protein engineering, pharmacological assays and structural studies, we develop maternally selective heavy-chain-only antibody ('nanobody') antagonists against the angiotensin II type I receptor and uncover the unusual molecular basis of their receptor antagonism...
May 14, 2024: Nature Chemical Biology